Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262821 · ClinicalTrials.gov registry record · Phase 3
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00262821: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00262821 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 402 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00262821, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Cisplatin and tirapazamine may make tumor cells more sensitive to radiation therapy. It is not yet known whether giving cisplatin together with radiation therapy is more effective with or without tirapazamine in treating cervical cancer.
Interventions
- DRUG cisplatin
- DRUG tirapazamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262821
The ClinicalTrials.gov registry entry for NCT00262821 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00262821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262821 about?
NCT00262821 is a clinical study titled "Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer". This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in different ways to stop t...
What is the current status of trial NCT00262821?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2006-02. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00262821?
The interventions under investigation include: cisplatin (DRUG), tirapazamine (DRUG).
Who is sponsoring clinical trial NCT00262821?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.